Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsglobalhealth Hospital Outpatient Infusion Coverage…
    Ask Trek AI about this page
    CurrentglobalhealthPolicy GH-ADM-003

    Site of Care (hospital outpatient infusion) coverage criteria

    Customize your policy alerts

    Sign up for globalhealth Policy GH-ADM-003 alerts

    Get alerted when Policy GH-ADM-003 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines when hospital outpatient facility infusion is medically necessary versus preferred alternate sites (home/office) for commercial GlobalHealth members; applies to outpatient injectable drugs/biologics requiring infusion.

    Policy Summary
    Payerglobalhealth
    PolicySite of Care (hospital outpatient infusion) coverage criteria
    Policy CodePolicy GH-ADM-003
    Change TypeClarificationRemoval
    Effective DateMar 1, 2019
    Last ReviewJan 1, 2020
    Next Review Date
    Key ActionObtain prior authorization for injectable drugs or biologics and submit documentation demonstrating the member meets at least one medical necessity criterion (1.1–1.4).
    SourceLink
    POLICY UPDATE CHANGES

    Clarified language in 1.1.1 regarding physical or cognitive impairments as justification for hospital outpatient infusion.

    Removed 'infed' from list of applicable drugs.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4
    Primary criteria bullets
    10+Drug groups listed
    CommercialLines of business

    Coverage Criteria — Site of Care for Infusion

    The policy was revised in January 2020 to remove the drug infed from the list of applicable medications. No other explicit drug exclusions are listed in the policy revision notes.

    Hospital outpatient facility infusion is not supported when none of criteria 1.1–1.4 are met — i.e., when the member is medically stable for administration in a preferred alternate place of service, first-dose requirements can be met in that preferred place of service, the drug is available for administration outside the hospital (not limited distribution), and the member has access to home or office-based infusion providers.

    inv-11: Criteria count — Any one of criteria 1.1–1.4 must be met
    Required number of criteriaAny one of criteria 1.1–1.4 must be met for hospital outpatient facility infusion to be medically necessary.
    Criterion 1.1Member is medically unstable for administration at alternate preferred place of service as documented by one or more subcriteria (see 1.1.1–1.1.2).
    Criterion 1.2First dose may be given at physician facility of choice when first‑dose requirements cannot be met by preferred place of service or member‑specific factors prevent administration at preferred place of service.
    Criterion 1.3Requested drug is subject to limited distribution and is not available for administration at non‑hospital outpatient facilities or for home infusion.
    Criterion 1.4Member lacks access to a home infusion or office‑based provider within his/her geographic area.

    Coding — Affected Drugs and Procedure Codes

    Covered CPT Codes headerCPT
    No codes listed
    Alpha 1 Proteinase InhibitorsHCPCSCovered
    J0256Aralast; Prolastin-C; Zemaira (alpha1 proteinase inhibitors)
    J0257Glassia (alpha1 proteinase inhibitor)
    Enzyme Replacement DrugsHCPCSCovered
    J1931Aldurazyme (laronidase)
    J1786Cerezyme (Imiglucerase)
    J3060Eleyso (taliglucerase alfa)
    J0180Fabrazyme (agalsidase)
    J0221Lumizyme (alglucosidase alfa)
    J1322Vimizim (elosulfase alfa)
    J3385Vpriv (velaglucerase alfa)
    Blood Clotting FactorsHCPCSCovered
    J7210Afstyla (antihemophilic factor (recombinant) single chain)
    J7192Advate; Helixate; Kogenate FS (antihemophilic factor (recombinant) / human variants)
    J7186Alphanate (antihemophilic factor/von Willebrand factor complex (human))
    J7194AlphaNine; Bebulin; Mononine (factor IX / factor IX complex codes)
    J7201Alprolix (coagulation factor IX (recombinant), Fc fusion protein)
    J7195Benefix; Ixinity (coagulation factor IX (recombinant))
    J7175Coagadex (coagulation factor X (human))
    J7180Corifact (factor XIII concentrate (human))
    J7205Eloctate (antihemophilic factor (recombinant), Fc fusion protein)
    J7198Feiba NH (anti - inhibitor coagulant complex)
    1–10 of 23
    1/3
    Immune GlobulinHCPCSCovered
    J1556Bivigam (immune globulin)
    J1555Cuvitru (immune globulin)
    J1572Flebogamma (immune globulin)
    J1566Gamastan S/D (immune globulin)
    J1569Gammagard S/D (immune globulin)
    J1561Gammaked; Gamunex (immune globulin)
    J1559Hizentra (immune globulin)
    J1460HyQvia (immune globulin)
    J1560HyQvia (immune globulin)
    J1568Octagam (immune globulin)
    1–10 of 11
    1/2
    Rheumatology/ImmunologyHCPCSCovered
    J3262Actemra IV (tocilizumab)
    J3380Entyvio (vedolizumab)
    Q5103Inflectra (infliximab-dyyb)
    J0129Orencia IV (abatacept)
    J1745Remicade (infliximab)
    Q5104Reflexis (infliximab-abda)
    J1602Simponi Aria (golimumab)
    Other listed drugsHCPCSCovered
    J7207Adynovate
    J0490Benlysta (belimumab)
    J0597Berinert
    Q0318Feraheme (ferumoxytol)
    Q0319Feraheme (ferumoxytol)
    J1447Granix
    J1439Injectafer (ferric carboxymaltose)
    J0202Lemtrada
    J2820Leukine
    J1442Neupogen
    1–10 of 19
    1/2

    Provider Actions — Authorization, Documentation, and Denials

    Prior Authorization

    Prior authorization required for injectable drugs/biologics

    Prior authorization is required for injectable drugs or biologics; requests are reviewed using pharmacologic criteria.

    Note

    Additional provider-action note

    No additional provider-action notes are specified in the source policy beyond the prior authorization, documentation, and denial language; follow the other listed provider actions for authorization, documentation, and site-of-care criteria as applicable.

    Documentation Required

    Documentation must support one of criteria 1.1–1.4

    Site of Care — Hospital Outpatient vs Alternate Settings

    Step Therapy

    Site‑of‑care requirement for hospital outpatient infusion

    Hospital outpatient facility infusion is considered medically necessary only when one or more of criteria 1.1–1.4 are met; otherwise the preferred sites of administration are home or office.

    • If criteria 1.1–1.4 are not documented, arrange infusion at home or office where appropriate.

    Background

    Many infused medications can be safely administered in the home or an office setting when the member is stable and appropriate supports exist. Hospital outpatient infusion is reserved for members who meet one or more specific criteria — for example, those who are medically unstable due to physical or cognitive impairments, have a history of severe infusion reactions that cannot be managed in non-hospital settings, require a first dose that cannot be administered in the preferred site, have a drug that is limited distribution, or lack geographic access to alternative infusion providers.

    Definitions — Key Terms

    inv-17: Medically unstable — definition for 'medically unstable' for alternate place of service
    DefinitionMedically unstable for alternate place of service: documented conditions that make administration in home or office settings an unnecessary health risk (see 1.1.1–1.1.2).
    1.1.1 (example)Physical or cognitive impairments such that home infusion or other preferred place of service would present an unnecessary health risk.
    1.1.2 (example)Previously documented severe or potentially life‑threatening adverse event during or following infusion of the prescribed drug that cannot be managed through pre‑medication in the home or office setting.
    Documentation neededClinical documentation must demonstrate the specific impairment or prior severe infusion reaction that justifies hospital outpatient administration.

    Revision History

    January 2020policy_revisionLatest

    Clarified language in criterion 1.1.1 regarding physical or cognitive impairments and removed 'infed' from the list of applicable drugs.

    Policy Summary
    Payerglobalhealth
    PolicySite of Care (hospital outpatient infusion) coverage criteria
    Policy CodePolicy GH-ADM-003
    Change TypeClarificationRemoval
    Effective DateMar 1, 2019
    Last ReviewJan 1, 2020
    Next Review Date
    Key ActionObtain prior authorization for injectable drugs or biologics and submit documentation demonstrating the member meets at least one medical necessity criterion (1.1–1.4).
    SourceLink
    On This Page
    Coverage Criteria — Site of Care for InfusionCoding — Affected Drugs and Procedure CodesProvider Actions — Authorization, Documentation, and DenialsSite of Care — Hospital Outpatient vs Alternate SettingsBackgroundDefinitions — Key TermsRevision History

    Documentation submitted with the request must support at least one of the medical necessity criteria (1.1–1.4), e.g., evidence of medical instability (including 1.1.1 physical or cognitive impairments), prior severe or potentially life‑threatening infusion reaction, limited distribution of the drug, or lack of access to home/office infusion providers.

    • Support for 1.1: evidence of medical instability, including physical or cognitive impairments (1.1.1) or prior severe infusion adverse event (1.1.2).
    • Support for 1.2: documentation that first-dose requirements cannot be met in preferred place of service.
    • Support for 1.3: evidence the drug is limited distribution and not available for non-hospital administration.
    • Support for 1.4: documentation that member lacks access to home or office infusion in their geographic area.
    Denial Risk

    Denial risk if no medical necessity criteria met

    Requests for hospital outpatient infusion may be denied if none of the medical necessity criteria (1.1–1.4) are met.

    • Denial risk applies when the member is stable for alternate sites, first-dose requirements can be met in preferred place of service, the drug is available for home/office administration, and the member has access to home/office infusion providers.